Table 4 – Studies using the Orthostatic hypotension Questionnaire Scores as an outcome

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author(s), Year** | | **Population** | **Trial Design (N)** | **Symptom Scoring questionnaire** | **Experimental Medication (Dose)** | **Experimental Change in mean score (SD)** | **Control Medication** | **Control change in mean score** |
| Byun 2017 (12) | | Patients with symptomatic nOH | RCT with open label period (87) | OHQ | Pyridostigmine (30mg BD) | OHQ composite score: -9.6 (NA) | Midodrine (2.5mg BD) | OHQ composite score: -15\*\* (NA) |
| Pyridostigmine (30mg BD) and midodrine (2.5mg BD) | OHQ composite score: -12\*\* (NA) |
| Byun 2020 (16) | | Patients with symptomatic nOH | RCT with open label period (50) | OHQ | Atomoxetine (18mg OD) | OHQ composite score: -9.7\*\* (NA) | Midodrine (5mg BD) | OHQ composite score: -4.1 (NA) |
|
| Hauser 2014 (22) | | Parkinson's disease patients with nOH | Double blinded RCT (51) | OHQ | Droxidopa (100-600mg TDS) | OHQ composite score: -2.2 (2.4) | Placebo | OHQ composite score: -2.1 (2.5) |
| Hauser 2015 (23) | | Parkinson's disease patients with nOH | Double blinded RCT (147) | OHQ | Droxidopa (100-600mg TDS) | OHQ composite score: -2.2 (2.29) OHSA item 1 at week 1: -2.3\* (2.95) | Placebo | OHQ composite score: -2.0 (2.18) OHSA item 1 at week 1: -1.3 (3.16) |
| Isaacson 2016 (24) | | Patients with a clinical diagnosis of symptomatic nOH | Open label prior to double blinded RCT (75) | OHQ | Droxidopa (100-600mg TDS) | OHQ composite score vs open label: +0.11 (NA) | Placebo | OHQ composite score vs open label: 0 (NA) |
| Kaufmann 2014 (41) | | Symptomatic nOH due to PD, PAF, MSA, nondiabetic autonomic neuropathy, or dopamine-β-hydroxylase deficiency | Double blinded RXT (162) | OHQ | Droxidopa (100-600mg TDS) | OHQ composite score: -1.83\* (2.07)  Symptom Composite score: -1.68 (2.13) | Placebo | OHQ composite score: -0.93 (1.69)  Symptom composite score: -0.95 (1.9) |
| Okamoto 2012 (13) | | Patients with severe peripheral autonomic failure | Single blinded, crossover RCT (12) | OHQ | Yohimbine (5.4mg) | OHQ composite score: -1.2 (NA) | Placebo | OHQ composite score: +2 (NA) |
| Atomoxetine (18mg) | OHQ composite score: --2.5 (NA) |
| Yohimbine (5.4mg) and Atomoxetine (18mg) | OHQ composite score: -9.6\* (NA) |
| Okamoto 2019 (14) | | Patients with severe nOH | Single blinded, crossover RCT (10) | OHQ | Pyridostigmine (60mg) | OHQ composite score: -2.7 (NA) | Placebo | OHQ composite score: -6 (NA) |
| Atomoxetine (18mg) | OHQ composite score: -8.7 (NA) |
| Pyridostigmine (60mg) and Atomoxetine (18mg) | OHQ composite score: -9.3\* (NA) |
| Ramirez 2014 (15) | | Patients with severe autonomic failure | Single blinded, crossover, RCT (69) | OHQ | Atomoxetine (18mg) | OHQ symptom score vs placebo: 0.4 SQRT\*1 (NA) | Placebo | NA |
| Midodrine (5-10mg) | OHQ symptom score vs placebo: 0.6 SQRT (NA) |
|  |

1The pre- and post-treatment OHQ and Q1 scores were square-rooted transformed (SQRT), exact figures for pre vs post medication OHQ scores were not available

\* p<0.05

\*\* p< 0.01